Sartor O, de Bono J, Chi KN, et al. - This international, open-label, phase 3 trial was undertaken to test lutetium-177 ( ¹⁷⁷ Lu)–PSMA(prostate-specific membrane antigen)-617 (a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment) in patients suffering from metastatic castration-resistant prostate cancer. The participants were patients who previously received at least one androgen-receptor–pathway inhibitor and one or two taxane regimens and had undergone PSMA-positive gallium-68–labeled PSMA-11 positron-emission tomographic–computed tomographic scans. Patients were randomized in a 2:1 ratio to undergo either ¹⁷⁷ Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. According to findings, prolongation of imaging-based progression-free survival and overall survival was conferred by radioligand therapy with ¹⁷⁷ Lu-PSMA-617 when added to standard care in patients suffering from advanced PSMA-positive metastatic castration-resistant prostate cancer.